ERBB2 and neoplasm: Undetectable circulating tumor DNAActionable driver mutations associated with durable responses (eg, ALK, EGFR, HER2)Markers of response to immunotherapy (eg, PD-L1 expression, high TMB, MSI-high status)Early complete metabolic response on PET imaging